Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PVX-410 · 1 trial · 1 indication
To assess the safety of the vaccine and PDL1 inhibitor.
| Arm | Type | Description |
|---|---|---|
| PVX-410 and Durvalumab | EXPERIMENTAL | Each patient will receive 6 PVX-410 vaccine injections and 2 infusions of Durvalumab. * The injection of PVX-410 will be co-administered with Hiltonol every 2 weeks for 6 injections. * The infusion of Durvalumab will be given on the day of the 4th and 6th PVX-410 injection, for a total of 2 infusions. |
| Name | Type | Description |
|---|---|---|
| PVX-410 | BIOLOGICAL | This is a Vaccine that will be injected intramuscularly as a mixture with an adjuvant. |
| Durvalumab | BIOLOGICAL | This is an intravenous infusion of a monoclonal antibody. |
| Hiltonol | DRUG | This is an intramuscular injection of an adjuvant to enhance the immune response to vaccine. |
Inclusion Criteria: * Written informed consent and any locally-required authorization obtained from the patient prior to performing any protocol-related procedures, including Screening evaluations. * Females, ≥18 years at time of study entry. * HLA-A2 positive by deoxyribonucleic acid (DNA) sequenc...
Top 20 of 82 competitors